{"nctId":"NCT02707601","briefTitle":"Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment","startDateStruct":{"date":"2016-04-01","type":"ACTUAL"},"conditions":["HIV-1 Infection","HCV Infection"],"count":150,"armGroups":[{"label":"E/C/F/TAF + LDV/SOF","type":"EXPERIMENTAL","interventionNames":["Drug: E/C/F/TAF","Drug: LDV/SOF"]},{"label":"F/R/TAF + LDV/SOF","type":"EXPERIMENTAL","interventionNames":["Drug: F/R/TAF","Drug: LDV/SOF"]}],"interventions":[{"name":"E/C/F/TAF","otherNames":["Genvoya®"]},{"name":"F/R/TAF","otherNames":["Odefsey®"]},{"name":"LDV/SOF","otherNames":["Harvoni®","GS-5885/GS-7977"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Chronic genotype (GT) 1, HCV infected, male and non-pregnant/ non-lactating female individuals, without cirrhosis, treatment-naive or treatment-experienced with interferon (IFN) +/- ribavirin (RBV) +/- HCV protease inhibitor (PI).\n* Compensated cirrhotic individuals must be HCV treatment-naive.\n* No prior treatments with NS5A and NS5B or any HCV direct acting antivirals, except boceprevir, telaprevir and simeprevir, in combination with IFN and RBV\n* Currently on an ARV regimen (2 NRTI + a third agent) without change for 6 months prior to screening.\n* Documented plasma HIV-1 RNA levels \\< 50 copies/mL (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL) for ≥ 6 months preceding the screening visit. After reaching HIV-1 RNA \\< 50 copies/mL, single values (\"blips\") of HIV-1 RNA ≥ 50 copies/mL followed by resuppression is allowed.\n* For individuals with 3 or more prior ARV regimens, a regimen history should be provided for approval by the Sponsor.\n\n  * Note: Individuals that changed from TDF to TAF less than 6 months ago will be eligible as long as the TDF/ TAF change was the only change to the regimen.\n* Plasma HIV-1 RNA level \\< 50 copies/mL at the screening visit\n* Have no documented resistance to any of the HIV study agents at time in the past, including but not limited to the reverse transcriptase resistance mutations K65R, K70E, K101E/P, E138A/G/K/R/Q, V179L, Y181C/I/V, M184V/I, Y188L, H221Y, F227C, M230I/L, the combination of K103N+L100I, or 3 or more thymidine analog associated mutations (TAMs) that include M41L or L210W (TAMs are M41L, D67N, K70R, L210W, T215Y/F, K219Q/E/N/R). If a historical genotype prior to first ARV is not available or individual had 3 or more prior ARV regimens, individual will have proviral genotype analysis for archived resistance prior to Day 1.\n* No history of HIV virologic failure\n* No evidence of Hepatitis B infection\n* Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min as estimated by Cockcroft-Gault formula\n\nNote: Other protocol defined Inclusion/ Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With HCV RNA < LLOQ at 12 Weeks After Discontinuation of LDV/SOF Treatment (SVR12)","description":"Sustained Virologic Response (SVR12) was defined as HCV RNA \\< the lower limit of quantitation (LLOQ) at 12 weeks after stopping LDV/SOF treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"95.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at 4 Weeks After Discontinuation of LDV/SOF Treatment (SVR4)","description":"SVR4 was defined as HCV RNA \\< LLOQ at 4 weeks after stopping LDV/SOF treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL (Virologic Failure) 24 Weeks After Start of the F/TAF-Based Regimen Using Modified FDA Snapshot Algorithm","description":"The percentage of participants with HIV-1 RNA ≥ 50 copies/mL 24 weeks after start of the F/TAF-based regimen were analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing Grades 1 Through 4 Adverse Events After Switch to E/C/F/TAF or F/R/TAF Throughout the Study and During Coadministeration With LDV/SOF Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","spread":null},{"groupId":"OG001","value":"69.4","spread":null},{"groupId":"OG002","value":"83.8","spread":null},{"groupId":"OG003","value":"79.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":74},"commonTop":["Cough","Upper respiratory tract infection","Urinary tract infection","Arthralgia","Headache"]}}}